Location Directory

Clinical trials in Cincinnati, Ohio

This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10564

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib oral treatment, Ocrelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 45
States / cities: Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 40 more

Conditions: Proteinuric Kidney Disease
Interventions: VX-147, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 10 Years to 65 Years
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 223
States / cities: Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more

Conditions: Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions: Computed Tomography, Magnetic Resonance Imaging, Tazemetostat; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 581
States / cities: Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 65 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 857
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more

Conditions: Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tamoxifen Citrate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 559
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 356 more

Conditions: Bipolar Disorder Type I With Mania
Interventions: KarXT, Lithium, Valproate, Lamotrigine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 61
States / cities: Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more

Conditions: Autoimmune Pulmonary Alveolar Proteinosis
Interventions: Molgramostim nebulizer solution; Drug
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 12
States / cities: Los Angeles, California • Gainesville, Florida • Baltimore, Maryland + 9 more

Conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Interventions: Codrituzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Major Depressive Disorder
Interventions: ALTO-300, Placebo; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 75
States / cities: Phoenix, Arizona • Yuma, Arizona • Rogers, Arkansas + 64 more

Conditions: ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions: Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham; Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 26 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions: Pegozafermin, Placebo; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 150
States / cities: Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 123 more

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Pumitamig, Pembrolizumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 41
States / cities: Daphne, Alabama • Bullhead City, Arizona • Glendale, Arizona + 37 more

Clinical trials in Cincinnati, Ohio

Filter and sort this location

Live official records

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Molgramostim Nebulizer Solution Expanded Access Program Protocol

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Study of ALTO-300 in MDD

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)